A blood screening is the process of laboratory testing for extracting blood prior to blood transfusion. The test is performed to ensure that recipients receive safe blood products. There are various blood screening procedures for donated blood to ensure that blood units are safe. Blood samples collected during donation undergo laboratory screening for Transfusion-Transmissible Infections (TTIs). In screening technique, blood sample is tested for evidence of certain infectious disease pathogens such as hepatitis B and C viruses and human immunodeficiency virus (HIV). There are different types of assay used for blood screening, which include Immunoassays (IAs) and nucleic acid amplification technology (NAT) assays. Immunoassays (IAs) is further subcategorized into enzyme immunoassays (EIAs), chemiluminescent immunoassays (CLIAs), haemagglutination (HA)/particle agglutination (PA) assays, and rapid/simple single-use assays (rapid tests).

Blood Screening Market- Drivers

Increasing demand for NAT over ELISA (enzyme-linked immunosorbent assay) test due to high sensitivity and specificity for viral nucleic acid is boosting growth of the blood screening market. For instance, in 2018, Grifols received approval from the U.S. Food & Drug Administration (FDA) for two blood screening assays- Procleix Ultrio Elite and Procleix WNV. Both assays run on the fully automated NAT blood screening platform: Procleix Panther system. The Procleix Panther system with these assays helps blood centers to efficiently screen for infectious diseases and eliminates the need of batch processing.

Increasing number of blood donations campaigns by the government, blood donor agencies, and NGO’s are expected to propel growth of the blood screening market. For instance, according to the WHO reported data in June 2017, around 112.5 million blood donations are collected globally and around half of these are collected in high-income countries, highlighting 19% of the world’s population. Moreover, increase in initiatives by the government to create awareness among the people regarding safety of the donated blood is expected to drive growth of the market. For instance, in 2014, World Health Organization (WHO) recommended to establish a national blood system with well-organized and coordinated blood transfusion services, effective evidence-based and ethical national blood policies, and legislation and regulation that can provide sufficient and timely supplies of safe blood and blood products to meet the transfusion needs of all patients.

However, shortages of trained staff and poor quality systems, which results in inefficient screening systems, inadequate procedures for identification, and misidentification of patient or donor blood samples are some of the factors restraining growth of the market.

Blood Screening Market- Regional Analysis

On the basis of region, the global blood screening market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Geographically, North America is expected to dominate the blood screening market, owing to acquisitions by major players in the region. For Instance, in July 2017, Grifols acquired the NAT (Nucleic Acid Testing) donor screening unit from the U.S. Company Hologic for a purchase price of US$ 1,850 Million. This agreement bound to research, development, and manufacture of assays and instruments activities by using NAT technology that allows detection of infectious agents present in blood and plasma donations, contributing to greater transfusion safety.

Asia Pacific is expected to witness significant growth in the blood screening market due to increasing government initiatives and rising awareness regarding transmission of diseases during blood transfusion. For instance, in June 2015, a National Blood Donor Vigilance Programme (NBDVP) was launched in India on the World Blood Donor Day. The objectives of the NBDVP is to increase blood donation frequency and reduce the frequency of adverse event and to analyze the risk factor and evaluate preventive measure.

Blood Screening Market- Competitive Landscape

Key Player operating in the blood screening market include Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers (A Subsidiary of Siemens AG), Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (A Subsidiary of Danaher Corporation) and Becton, Dickinson and Company.

Key Development

In July 2019, Abbott Laboratories, received the U.S. Food and Drug Administration (FDA) approval for its new blood and plasma screening Alinity s System. Alinity s System is designed to screen blood and plasma more efficiently in less space and also generate the test results consuming less tume and minimum human error.
In 2018, LifeCell International Pvt. Ltd launched RightStart, an integrated DNA-based screening for the diagnosis of more than 50 medical conditions among newborn patients.
In 2017, Clinical Genomics Pty Ltd, launched circulating tumor DNA (ctDNA) blood-based test for the detection of colorectal cancer.
In 2016, Hologic, Inc and Grifols, S.A being in a partnership agreement, received the US Food and Drug Administration (FDA) approval for its Procleix Zika virus blood screening assay.
In 2016, F. Hoffmann-La Roche Ltd, received US Food and Drug Administration (FDA) approval for its cobas MPX test applicable with analyzers like cobas 6800 and 8800 Systems for the detection of HIV-1, HIV-2, HBV and HCV.

Blood Screening Market- Taxonomy

By Technology: